Why so many people take these pills
Direct oral anticoagulants, or DOACs, are some of the most prescribed drugs in the world. You might know them by names like dabigatran (Pradaxa), rivaroxaban (Xarelto), apixaban (Eliquis), or edoxaban (Savaysa).
Doctors prescribe them to prevent strokes in people with atrial fibrillation (an irregular heartbeat). They also treat and prevent dangerous blood clots in the legs and lungs.
Millions of people take them every day. They mostly replaced warfarin, an older blood thinner that needed constant blood tests and a strict diet.
But DOACs are not perfect. Some people still bleed too much. Others form clots even while on the drug. And until now, doctors had few clues about why.
The old way of thinking
For a long time, dosing was based on simple things. Your weight. Your age. Your kidney function.
If those numbers looked normal, you got the standard dose. End of story.
But here's the twist. Researchers kept seeing huge differences in how patients responded. Two people with the same age, weight, and kidneys could have very different drug levels in their blood.
Something else was going on. And scientists started to suspect DNA.
How your genes get involved
Think of your body as a busy airport. When you swallow a pill, it has to be "processed" by special workers. Some workers break the drug down. Others move it from one place to another. Still others push it back out of cells so it doesn't build up.
These "workers" are proteins. And the instructions for building them come from your genes.
Now imagine a small typo in those instructions. The worker might be a little slower. Or a little faster. Or a little less careful.
That tiny typo, called a polymorphism, can change how much drug actually reaches your bloodstream. And that changes whether the drug helps you, harms you, or does nothing at all.
A team of scientists pulled together every good study they could find on DOACs and genetics. They searched four major medical databases through October 2025.
They ended up with 39 studies covering more than 13,000 patients. For 19 of those studies, they had enough data to combine the numbers and look for patterns.
Several specific gene variants stood out.
For dabigatran, people with one version of a gene called CES1 had lower drug levels in their blood. They also had less bleeding. That makes sense: less drug, less risk.
For rivaroxaban, a variant in a gene called ABCB1 was tied to lower drug levels too. Some ABCB1 changes also affected bleeding risk.
For apixaban, similar ABCB1 changes seemed to lower bleeding risk. And for edoxaban, a gene called SLCO1B1 may shift how the drug breaks down.
In plain English: your genetic makeup may quietly decide whether your standard dose is too strong, too weak, or just right.
This does not mean genetic testing for blood thinners is ready for your next doctor visit.
Where this fits in the bigger picture
This is not the first time genes have shaped how we use medicines. Cancer care, depression treatment, and even some pain medications already use genetic clues to guide dosing.
Blood thinners have lagged behind, partly because DOACs were designed to be "one size fits most." This new review suggests that promise may have been a little too optimistic.
It also fits a wider shift in medicine called pharmacogenomics. That's a fancy word for matching the right drug, at the right dose, to the right person, based on their DNA.
If you take a DOAC, do not change anything based on this study. Do not stop your medicine. Do not ask for a gene test just yet.
But it is a fair conversation to have at your next checkup. Ask your doctor how they monitor you for bleeding or clotting. Tell them about any unusual bruising, dark stools, or nosebleeds right away.
The takeaway is simple. Your response to a blood thinner is more personal than doctors once thought.
The honest limits
The researchers were upfront. Most of the included studies were small. Many were observational, meaning they watched what happened rather than testing changes in a careful trial.
The results also varied a lot from study to study. And some gene variants were only studied in certain ethnic groups, which limits how broadly the findings apply.
In short, the signal is real, but it is not yet strong enough to guide care.
What comes next
The authors call for large, well-designed trials. These would test whether choosing a DOAC dose based on your genes actually leads to fewer strokes and fewer bleeds compared with standard dosing.
That kind of research takes years. But the payoff could be big: safer, smarter blood thinner use for millions of people.
For now, the message is one of patience. The science is moving in the right direction. Your DNA may one day help your doctor pick the perfect pill for you.